NPF turns 10 companies in to FDA, FTC
This article was originally published in The Tan Sheet
The Natural Products Foundation's Truth in Advertising program seeks to educate advertisers and ensure marketing complies with rules in the Food, Drug, and Cosmetic Act and Dietary Supplement Health and Education Act. Of the 21 companies the program contacted about questionable marketing, 10 failed to amend their ads and, as a result, the program notified the FDA and Federal Trade Commission. The program also gave the regulators information about seven other Web sites that allegedly make inappropriate disease treatment claims, including claims to cure H1N1, NPF announced Oct. 29
You may also be interested in...
Dietary supplement industry trade groups offer enforcement help against fraudulent H1N1 flu virus claims with their second joint statement this year noting that federal regulations do not allow supplements to make disease claims. The associations note Dec. 7 that FDA and the Federal Trade Commission issued 147 warning letters since May on products making H1N1 prevention or cure claims. "FTC informed us that they were not getting the results they wanted," American Herbal Product Association President Michael McGuffin said in a Dec. 10 e-mail. Natural Products Association Executive Director John Gay said that since the groups' May statement, the cold and flu season started and flu-related claims are more prevalent. The Natural Products Foundation's Truth in Advertising program in October referred 10 firms to FDA and FTC after they failed to amend their ads to comply with regulations (1"The Tan Sheet" Oct. 29, 2009, In Brief). FDA says the bogus H1N1 claims it is finding have slowed since May from seven to 10 a day to as many in a week (2"The Tan Sheet" Oct. 19, 2009). "We are continuing with the same enforcement effort that we have used," a spokesman said. The Consumer Healthcare Products Association, the Council for Responsible Nutrition and the United Natural Products Alliance also signed the joint industry statement
Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.
Lannett has begun marketing a US rival to Adderall XR through a partnership with Elite and SunGen. But the product will face competition from a range of other generics.